At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AGIO Agios Pharmaceuticals
Pre-Mkt 06-05 04:49:53 EDT
28.79
+1.11
+4.01%
High29.32Low27.94Vol648.16K
Open28.12D1 Closing27.68Amplitude5.00%
Mkt Cap1.71BTradable Cap1.46BTotal Shares59.47M
T/O18.71MT/O Rate1.28%Tradable Shares50.62M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Agios Pharmaceuticals, Oscotec Sign Global Licensing Agreement for Cevidoplenib
MT Newswires Live  ·  06-01
Agios Pharmaceuticals, Oscotec Sign Global Licensing Agreement for Cevidoplenib
Agios posts investor deck on cevidoplenib licensing deal in immune thrombocytopenia (ITP)
Reuters  ·  06-01
Agios posts investor deck on cevidoplenib licensing deal in immune thrombocytopenia (ITP)
Agios Pharmaceuticals enters license pact with Oscotec to develop cevidoplenib
TIPRANKS  ·  06-01
Agios Pharmaceuticals enters license pact with Oscotec to develop cevidoplenib
Agios licenses exclusive global rights from Oscotec to SYK inhibitor cevidoplenib in deal with USD 25 million upfront payment
Reuters  ·  06-01
Agios licenses exclusive global rights from Oscotec to SYK inhibitor cevidoplenib in deal with USD 25 million upfront payment
Agios Pharmaceuticals - Oscotec to Receive $25 Mln Upfront Plus Milestone Payments and Tiered Royalties
THOMSON REUTERS  ·  06-01
Agios Pharmaceuticals - Oscotec to Receive $25 Mln Upfront Plus Milestone Payments and Tiered Royalties
Agios Pharmaceuticals - Oscotec Eligible for up to $140 Mln in Development and Regulatory Milestones
THOMSON REUTERS  ·  06-01
Agios Pharmaceuticals - Oscotec Eligible for up to $140 Mln in Development and Regulatory Milestones
Agios Pharmaceuticals - Oscotec Retains Option for Exclusive Rights to Cevidoplenib in South Korea
THOMSON REUTERS  ·  06-01
Agios Pharmaceuticals - Oscotec Retains Option for Exclusive Rights to Cevidoplenib in South Korea
Agios Pharmaceuticals - Expects 2026 Operating Expense Guidance to Be Flat Compared to 2025
THOMSON REUTERS  ·  06-01
Agios Pharmaceuticals - Expects 2026 Operating Expense Guidance to Be Flat Compared to 2025
Agios Enters Exclusive Global License Agreement With Oscotec to Develop and Commercialize Next-Generation Syk Inhibitor Cevidoplenib
THOMSON REUTERS  ·  06-01
Agios Enters Exclusive Global License Agreement With Oscotec to Develop and Commercialize Next-Generation Syk Inhibitor Cevidoplenib
Agios Pharmaceuticals Is Maintained at Buy by B of A Securities
Dow Jones  ·  05-30
Agios Pharmaceuticals Is Maintained at Buy by B of A Securities
Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX), Agios Pharma (AGIO) and Healthequity (HQY)
TIPRANKS  ·  05-30
Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX), Agios Pharma (AGIO) and Healthequity (HQY)
Agios Pharmaceuticals price target lowered to $40 from $41 at BofA
TIPRANKS  ·  05-29
Agios Pharmaceuticals price target lowered to $40 from $41 at BofA
BUZZ-U.S. STOCKS ON THE MOVE-Tempus AI, SOLV Energy, Replimune
Reuters  ·  05-29
BUZZ-U.S. STOCKS ON THE MOVE-Tempus AI, SOLV Energy, Replimune
BRIEF-Agios Provides Update On Phase 2B Trial Of Tebapivat In Lower-Risk Myelodysplastic Syndromes
Reuters  ·  05-29
BRIEF-Agios Provides Update On Phase 2B Trial Of Tebapivat In Lower-Risk Myelodysplastic Syndromes
BUZZ-U.S. STOCKS ON THE MOVE-Costco, Firefly Aerospace, Agios
Reuters  ·  05-29
BUZZ-U.S. STOCKS ON THE MOVE-Costco, Firefly Aerospace, Agios
Agios Pharma Won't Advance Tebapivat for Lower-Risk Myelodysplastic Syndromes
Dow Jones  ·  05-29
Agios Pharma Won't Advance Tebapivat for Lower-Risk Myelodysplastic Syndromes
Agios Halts Development of Tebapivat in Lower-Risk MDS After Mid-Stage Trial Miss; Shares Drop Premarket
MT Newswires Live  ·  05-29
Agios Halts Development of Tebapivat in Lower-Risk MDS After Mid-Stage Trial Miss; Shares Drop Premarket
Agios will not advance tebapivat in lower-risk myelodysplastic syndromes
TIPRANKS  ·  05-29
Agios will not advance tebapivat in lower-risk myelodysplastic syndromes
Agios Pharmaceuticals Shares Fall 19% Premarket After Co to Stop Development of Its Blood Disorder Drug
THOMSON REUTERS  ·  05-29
Agios Pharmaceuticals Shares Fall 19% Premarket After Co to Stop Development of Its Blood Disorder Drug
Agios scraps blood disorder drug program after study miss
Reuters  ·  05-29
Agios scraps blood disorder drug program after study miss

Introduction

Company Name.
Agios Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Issue price:
--